Abstract 727P
Background
Several clinical studies has demonstrated promising tumor response rates with cadonilimab, a bi-specific antibody targeting PD-1 and CTLA-4, in patients with recurrent or metastatic cervical cancer (R/M CC). Cadonilimab received approval for the treatment of R/M CC in patients who have experienced progression following platinum-based chemotherapy, as of 29 June 2022, in China. This study aims to evaluate the efficacy and safety of cadonilimab in a real-world clinical setting.
Methods
We conducted a multicenter, retrospective study across 13 centers in China, examining cadonilimab’s efficacy and safety in 139 R/M CC patients treated at least one cycle of cadonilimab from July 2022 to October 2023. Treatment outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety profile, were analyzed. Biomarkers were explored.
Results
The median progression-free survival (PFS) was 8.1 months (95% CI, 5.8-10.2), while the median overall survival (OS) was not reached (95% CI, 8.1 to not estimable). Of the 129 efficacy-evaluable patients, The ORR was 38.8%, and the DCR was 72.1%. Additionally, 95.7% of the paitents experienced treatment-related adverse events. The most frequent adverse events were anemia (71.9%), hypoalbuminemia (70.5%) and decreased white blood cell count (56.1%). Grade 3-4 adverse events, with anemia (20.1%), decreased white blood cell count (17.2%), and decreased neutrophil count (14.4%) being the most common. Immune-related adverse events (irAEs) affected 78 patients (55.7%). The most common were hypothyroidism (31, 22.3%) and rash (20, 14.4%). Furthermore, 12 patients (8.6%) experienced Grade 3-4 irAE. Multivariate analysis confirmed that combined with radiotherapy and chemotherapy are independent predictors of OS. For progression-free survival (PFS), multivariate analysis specifically highlighted combined with radiotherapy and liver metastasis as independent prognostic factors.
Conclusions
Cadonilimab is efficacious and safe for patients with R/M CC, even in patients with PD-L1 CPS<1, in a real-world setting.
Clinical trial identification
NCT06140589.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01